The AHA, joined by the Association of American Medical Colleges and America's Essential Hospitals, today urged a federal appeals court to expedite their appeal of a lower court’s December dismissal of the groups’ lawsuit that sought to prevent Medicare payment cuts for many hospitals in the 340B Drug Pricing Program. Today’s request asked that the United States Court of Appeals for the District of Columbia Circuit establish an expedited schedule that would ensure completion of all briefing in the appeal by no later than the beginning of April and set a date for oral argument as soon as practicable upon completion of the briefing. The request to expedite briefing is joined by the hospitals that were part of the original lawsuit challenging the payment reduction – Eastern Maine Healthcare Systems in Brewer, ME, Henry Ford Health System in Detroit and Adventist Health System's Park Ridge Health in Hendersonville, NC. The lower court on Dec. 29 dismissed the lawsuit as premature, but it did not rule on the merits of the groups’ claim. The groups on Jan. 9 formally notified the court of their appeal.
 

Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to…
Headline
The AHA today voiced support () for the 340B Rebate Model Delay Act (H.R. 10770)in a letter to the bill’s House sponsors. The bipartisan bill would pause the…
Headline
The AHA, the Maine Hospital Association and four safety-net hospitals Oct. 9 filed a lawsuit in the U.S. District Court for the District of Maine challenging…
Headline
The AHA, the New Hampshire Hospital Association and 340B Health have filed an amicus brief supporting Mary Hitchcock Memorial Hospital’s request for a…
Headline
The Department of Health and Human Services’ Health Resources and Services Administration Oct. 1 announced approval of 10 drug companies to participate in the…